Priming reloaded?

Blood

Volumn 114, Issue 4, 2009, Pages 925-926

  Heuser, Michael ^a,b   Kuchenbauer, Florian ^b   Argiropoulos, Bob ^b   Sekulovic, Sanja ^b   Leung, Malina ^b   Stasiak, Marcin ^c   Ganser, Arnold ^a   Humphries, R Keith ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Gilead Sciences   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; MOL 27575; PLERIXAFOR; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CXCR4; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CELL COUNT; CELL POPULATION; CONTROLLED STUDY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; LETTER; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADJUVANT THERAPY; ANIMAL; BONE MARROW TRANSPLANTATION; CANCER STEM CELL; CELL MOTION; DRUG ADMINISTRATION; DRUG ANTAGONISM; EVALUATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; NOTE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; DRUG ADMINISTRATION SCHEDULE; GRANULOCYTE COLONY-STIMULATING FACTOR; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA; MICE; NEOADJUVANT THERAPY; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR4; TRANSPLANTATION CONDITIONING;

EID: 68249149655     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-217299     Document Type: Letter

References (9)

1. Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009;113:6206-6214.
2. Azab AK, Runnels JM, Pitsillides C, et al. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113:4341-4351.
3. Stasiak M, Mehlin C, Boni E, et al. Sulphonamide-based small molecule VLA-4 antagonists. Bioorg Med Chem Lett. 2003;13:3875-3878. (Pubitemid 37206527)
4. Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006;108:3898-3905. (Pubitemid 44864574)
5. Heuser M, Argiropoulos B, Kuchenbauer F, et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood. 2007;110:1639-1647. (Pubitemid 47443982)
6. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23:43-52.
7. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood. 2009;113:4711-4719.
8. Ottmann OG, Bug G, Krauter J. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol. 2007;44:183-192. (Pubitemid 47031229)
9. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-752. (Pubitemid 37010778)